Literature DB >> 21777792

Love triangle between Unc93B1, TLR7, and TLR9 prevents fatal attraction.

Miwa Sasai1, Akiko Iwasaki.   

Abstract

Unc93B1, a multitransmembrane ER-resident protein, controls intracellular trafficking of endosomal Toll-like receptors. In this issue of Immunity, Fukui et al. (2011) revealed that Unc93B1 regulates differential transport of TLR7 and TLR9 into signaling endosomes to prevent autoimmunity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21777792      PMCID： PMC3143494          DOI： 10.1016/j.immuni.2011.07.006

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  10 in total

1.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

Authors:  Sean R Christensen; Jonathan Shupe; Kevin Nickerson; Michael Kashgarian; Richard A Flavell; Mark J Shlomchik
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 2.  Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease.

Authors:  Ann Marshak-Rothstein; Ian R Rifkin
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

3.  UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.

Authors:  You-Me Kim; Melanie M Brinkmann; Marie-Eve Paquet; Hidde L Ploegh
Journal:  Nature       Date:  2008-02-27       Impact factor: 49.962

4.  Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking.

Authors:  Ryutaro Fukui; Shin-Ichiroh Saitoh; Atsuo Kanno; Masahiro Onji; Takuma Shibata; Akihiko Ito; Morikazu Onji; Mitsuru Matsumoto; Shizuo Akira; Nobuaki Yoshida; Kensuke Miyake
Journal:  Immunity       Date:  2011-06-16       Impact factor: 31.745

5.  Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3.

Authors:  Miwa Sasai; Melissa M Linehan; Akiko Iwasaki
Journal:  Science       Date:  2010-09-17       Impact factor: 47.728

6.  Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation.

Authors:  Jonathan A Deane; Prapaporn Pisitkun; Rebecca S Barrett; Lionel Feigenbaum; Terrence Town; Jerrold M Ward; Richard A Flavell; Silvia Bolland
Journal:  Immunity       Date:  2007-11-08       Impact factor: 31.745

7.  TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus.

Authors:  Kevin M Nickerson; Sean R Christensen; Jonathan Shupe; Michael Kashgarian; Daniel Kim; Keith Elkon; Mark J Shlomchik
Journal:  J Immunol       Date:  2010-01-20       Impact factor: 5.422

Review 8.  A cell biological view of Toll-like receptor function: regulation through compartmentalization.

Authors:  Gregory M Barton; Jonathan C Kagan
Journal:  Nat Rev Immunol       Date:  2009-06-26       Impact factor: 53.106

9.  A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus.

Authors:  O T Chan; L G Hannum; A M Haberman; M P Madaio; M J Shlomchik
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

10.  Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing.

Authors:  Ryutaro Fukui; Shin-ichiroh Saitoh; Fumi Matsumoto; Hiroko Kozuka-Hata; Masaaki Oyama; Koichi Tabeta; Bruce Beutler; Kensuke Miyake
Journal:  J Exp Med       Date:  2009-05-18       Impact factor: 14.307
  10 in total
  7 in total

1.  Adaptor Protein-3-Mediated Trafficking of TLR2 Ligands Controls Specificity of Inflammatory Responses but Not Adaptor Complex Assembly.

Authors:  Tanja Petnicki-Ocwieja; Aurelie Kern; Tess L Killpack; Stephen C Bunnell; Linden T Hu
Journal:  J Immunol       Date:  2015-09-30       Impact factor: 5.422

2.  TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Authors:  Ming-Fen Ho; James N Ingle; Tim Bongartz; Krishna R Kalari; Paul E Goss; Lois E Shepherd; Taisei Mushiroda; Michiaki Kubo; Liewei Wang; Richard M Weinshilboum
Journal:  Mol Pharmacol       Date:  2017-06-14       Impact factor: 4.436

Review 3.  TLRs and interferons: a central paradigm in autoimmunity.

Authors:  Dwight H Kono; Roberto Baccala; Argyrios N Theofilopoulos
Journal:  Curr Opin Immunol       Date:  2013-11-16       Impact factor: 7.486

4.  Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.

Authors:  Franziska Römmler; Monika Hammel; Anna Waldhuber; Tina Müller; Marion Jurk; Eugen Uhlmann; Hermann Wagner; Jörg Vollmer; Thomas Miethke
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

5.  Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis.

Authors:  Yixiao Tian; Biqing Huang; Jing Li; Xinping Tian; Xiaofeng Zeng
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

6.  Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells.

Authors:  Francesca Prete; Marco Catucci; Mayrel Labrada; Stefania Gobessi; Maria Carmina Castiello; Elisa Bonomi; Alessandro Aiuti; William Vermi; Caterina Cancrini; Ayse Metin; Sophie Hambleton; Robbert Bredius; Luigi Daniele Notarangelo; Mirjam van der Burg; Ulrich Kalinke; Anna Villa; Federica Benvenuti
Journal:  J Exp Med       Date:  2013-01-21       Impact factor: 14.307

7.  Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?

Authors:  Erika Aurora Martínez-García; Maria Guadalupe Zavala-Cerna; Andrea Verónica Lujano-Benítez; Pedro Ernesto Sánchez-Hernández; Beatriz Teresita Martín-Márquez; Flavio Sandoval-García; Mónica Vázquez-Del Mercado
Journal:  Front Immunol       Date:  2018-07-06       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.